5-Bromo-4-isopropylthiazol-2-amine (CAS 1025700-49-5), also named 2-amino-5-bromo-4-isopropylthiazole or 5-bromo-4-(propan-2-yl)-1,3-thiazol-2-amine, is a trifunctionalized aminothiazole building block with the molecular formula C₆H₉BrN₂S and a molecular weight of 221.12 g/mol. It presents as a white to off-white crystalline solid, is soluble in organic solvents including ethanol, dimethyl sulfoxide and chloroform, and is commonly supplied at ≥96% or ≥97% purity depending on the supplier and grade. The molecule’s commercial argument rests on three independent handles arrayed on a single rigid thiazole core. The bromine at the 5-position enables efficient palladium-catalysed cross-coupling—Suzuki-Miyaura, Buchwald-Hartwig and Sonogashira reactions—to install aryl, heteroaryl or alkyl substituents with defined vectors. The free amino group at the 2-position supports acylation, alkylation and urea formation, providing a second point of structural elaboration. The isopropyl group at the 4-position contributes steric bulk and lipophilicity, modulating metabolic stability and target selectivity without requiring additional synthetic steps. That combination—a cross-coupling handle, a nucleophilic handle and a built-in lipophilic steric element—is why the compound is used as a key intermediate for kinase inhibitors targeting cancer, inflammation and autoimmune disease, including JAK, BTK, CDK and PI3K programs, as well as for antiviral, antibacterial and antifungal agent development. The market is not a tonnage market. It is a research-to-pilot specialty chemical supplied in 100 mg to 25 g packages at catalogue scale, with indicative pricing of £13 for 250 mg and £31 for 1 g from one UK-based supplier, and kilogram-scale quantities available through custom synthesis. The qualifying question for buyers is therefore not “what does a kilogram cost” but “which supplier can deliver a reproducible lot, with lot-specific analytical data and clarity on the inventory and documentation status that a regulated program requires.”
Core Application Fields and Demand Architecture
Demand for 5-bromo-4-isopropylthiazol-2-amine concentrates in three functional arenas where the trifunctional thiazole scaffold provides a combination of reactivity and physicochemical profile that simpler aminothiazoles cannot replicate: kinase inhibitor discovery and development, antiviral and antimicrobial research, and custom synthesis for medicinal chemistry programs.
In kinase inhibitor discovery, the compound serves as a key intermediate for inhibitors targeting JAK, BTK, CDK and PI3K pathways. The 2-aminothiazole core is a privileged kinase-hinge-binding motif, and the 5-bromo substituent provides a point of attachment for the aryl or heteroaryl group that occupies the selectivity pocket adjacent to the hinge. The 4-isopropyl group modulates lipophilicity (predicted logP 3.19) and steric bulk, influencing membrane permeability and selectivity against off-target kinases. This is the segment where the building block’s value is highest, because the cost of an off-spec lot or a failed cross-coupling is measured in lost synthesis time and delayed SAR cycles rather than in the price of the gram. A lot that carries an unreported impurity or that fails to couple cleanly can produce a library member that requires chromatographic purification, and the medicinal chemist discovers the problem after the reaction rather than in incoming QC.
In antiviral, antibacterial and antifungal research, the aminothiazole scaffold appears in programs targeting infectious disease, and the 5-bromo handle allows the introduction of substituents that modulate spectrum and potency. The compound’s rigid thiazole core offers defined target-binding geometry, and the 2-amino group provides a site for acylation or sulfonylation that can be tuned for metabolic stability. This segment is smaller in volume than kinase discovery but connects the building block to anti-infective research funding that is less cyclical than commercial oncology spending.
Custom synthesis and medicinal chemistry programs form the third arena. Suppliers offer the compound as a catalogue building block and as a custom-synthesis starting point, and a program that begins with a 100 mg or 250 mg qualification lot may later require gram or tens-of-gram quantities under a locked specification. The supplier’s ability to follow that transition without changing the analytical method or the impurity profile is part of the product’s value.
Regulatory Profile: A GHS07 Irritant with an Inventory Status That Requires Supplier Confirmation
5-Bromo-4-isopropylthiazol-2-amine is not a CMR substance and is not on the SVHC Candidate List. Its regulatory identity is defined by a GHS07 irritant classification, an inventory status that is not consistently reported as “listed” across supplier documentation, and the analytical specifications that determine whether the material is fit for medicinal chemistry.
The hazard profile is that of a solid irritant. The GHS classification is GHS07 (Harmful/Irritant) with signal word “Warning” and hazard statements H302 (harmful if swallowed), H315 (causes skin irritation), H319 (causes serious eye irritation) and H335 (may cause respiratory irritation). These are handling hazards, not carcinogenicity, mutagenicity or reproductive toxicity classifications, and the required precautions are standard for a fine-chemical solid: wear protective gloves and eye/face protection, avoid breathing dust, use in a well-ventilated area, and store the container tightly closed under inert atmosphere at 2–8 °C, protected from light.
The inventory status is a qualification checkpoint rather than a definitive barrier. Supplier SDS documentation for this compound does not consistently state that it is listed on the TSCA Inventory; at least one distributor SDS advises buyers to “contact the supplier for inventory compliance status” rather than confirming a listing. For U.S.-facing programs, the buyer must therefore obtain a direct, lot-specific statement of TSCA status rather than relying on a generic catalogue field. If the substance is not listed, import for commercial purposes would ordinarily require a Premanufacture Notice or an applicable exemption, most commonly the R&D exemption for research quantities used under the supervision of a technically qualified individual. In the European Union, the compound has no EINECS number reported in some SDS documentation, and REACH registration obligations depend on the volume and the specific supplier’s registration status. For Russian and EAEU buyers, the practical documentation expectations are a Certificate of Analysis reporting identity and purity by HPLC, a Russian-language SDS reflecting the GHS07 classification, and confirmation that the material is the 5-bromo-4-isopropyl-2-amino substitution pattern rather than a positional analogue.
The analytical specification is where the regulatory and quality dimensions converge. The compound is typically supplied at ≥96% or ≥97% purity (HPLC), and a lot that has absorbed moisture or degraded during storage may still assay within specification but deliver poor results in a Suzuki or Buchwald coupling, so the supplier’s packaging and storage discipline are part of the product’s fitness for use.
Global Supply Structure and Manufacturer Differentiation
Global supply of 5-bromo-4-isopropylthiazol-2-amine is fragmented and research-oriented. The supplier landscape includes international research-chemical distributors and specialty producers such as Fluorochem, Matrix Scientific, AK Scientific, Aladdin, Macklin, Bide Pharmatech, BOC Sciences, CymitQuimica (Indagoo brand), Beyotime, GlpBio, EvitaChem, BenchChem and a cohort of Chinese custom-synthesis houses. Purity specifications span 95% to 98%, with 96–97% as the most common commercial grade, and package sizes range from 100 mg and 250 mg at catalogue scale to 1 g, 5 g, 10 g and 25 g, with kilogram quantities available on custom order. Production is concentrated in Asia-Pacific, particularly China, where established heterocyclic chemistry infrastructure and proximity to pharmaceutical research create a structural cost advantage for research-scale and custom-scale supply.
Differentiation operates on three axes. The first is analytical depth and lot-specific data. Suppliers that provide HPLC results for the specific lot, rather than a generic specification, reduce the buyer’s need to re-characterize material before use. In kinase discovery, where the building block is incorporated into a complex inhibitor and purification is expensive, the cost of an off-spec lot is measured in lost synthesis time rather than in the price of the gram. The second axis is substitution-pattern and purity control. The 5-bromo-4-isopropyl-2-amino pattern must be distinguished from positional isomers and from partially brominated or deaminated impurities. A lot that carries a positional impurity or residual starting material can behave differently in cross-coupling and introduce a downstream impurity that is difficult to purge. Suppliers that report lot-specific HPLC purity and confirm the substitution pattern give the medicinal chemist a defensible basis for use. The third axis is scale-up and custom-synthesis capability. A supplier that can follow a program from a 250 mg catalogue purchase to gram or tens-of-gram custom quantities, without changing the analytical method or the impurity profile, is more valuable than a catalogue vendor that cannot support the later stage.
Regional Demand Dynamics
Demand for 5-bromo-4-isopropylthiazol-2-amine follows the geography of medicinal chemistry and biotech R&D rather than the geography of chemical manufacturing.
North America and Europe are the principal demand centers for high-purity research-grade material, reflecting the concentration of kinase inhibitor discovery, antiviral and antimicrobial research, and contract research organizations in these regions. Demand is project-driven and small in absolute mass: a single medicinal chemistry group may purchase 250 mg to a few grams at a time, and a program that advances may require tens of grams. The U.S. market carries the additional inventory-status consideration described above, which tends to keep commercial flows at research scale unless an exemption or PMN pathway is established. European demand is similarly research-intensive, with buyers placing weight on supplier documentation and the ability to source from a supplier with a clear TSCA position for U.S.-linked programs.
Asia-Pacific, and China in particular, is the manufacturing and stock-holding hub for the compound. Chinese producers offer the building block at 96–98% purity across package sizes from grams to larger custom quantities, serving both domestic pharmaceutical R&D and export markets. The region’s demand is growing as domestic drug-discovery research expands, and Chinese suppliers are increasingly capable of providing lot-specific analytical data alongside the product. For Russian and EAEU buyers, China is the most accessible source of supply, and the practical qualification task centers on verifying the Certificate of Analysis and the SDS rather than on navigating a complex regulatory approval pathway.
Russia and the EAEU form a small, import-dependent contour. Demand comes from pharmaceutical R&D, medicinal chemistry groups and custom-synthesis service providers, and supply is sourced from Chinese and international catalogue vendors. There is no meaningful domestic production of the compound, and the practical constraint is availability at the required purity and package size rather than regulatory restriction. Buyers in the region place a premium on suppliers that can provide a Russian-language SDS, a lot-specific Certificate of Analysis and reliable delivery of small packages, because a delayed gram can stall a synthesis campaign.
Future Outlook and Strategic Imperatives
The commercial trajectory of 5-bromo-4-isopropylthiazol-2-amine is tied less to its own market size than to the kinase inhibitor and anti-infective programs it enables. The aminothiazole scaffold remains a privileged hinge-binding motif in medicinal chemistry, and the trifunctional substitution pattern—bromo for cross-coupling, amino for acylation or alkylation, isopropyl for lipophilicity and steric modulation—gives medicinal chemists a single building block that can generate diverse analogues without rebuilding the core. As JAK, BTK, CDK and PI3K programs advance, and as antiviral and antimicrobial research continues to seek new thiazole-based chemotypes, demand for well-characterized material with documented substitution pattern and lot-specific analytical data will grow.
Three structural forces will shape the supply landscape. First, analytical transparency and substitution-pattern confirmation will remain the primary differentiators. As programs mature, the building block’s purity and isomeric profile directly affect the purity of the final inhibitor, and buyers will increasingly require lot-specific HPLC data and confirmation of the 5-bromo-4-isopropyl-2-amino pattern rather than a nominal 96% figure. Second, the transition from catalogue to custom scale will separate suppliers that can support a program’s growth from those that can only fill a small-pack order. A supplier that can lock a specification at 250 mg and reproduce it at gram or tens-of-gram scale, with the same impurity profile, will be preferred for process development. Third, inventory and documentation clarity will matter more as programs advance beyond research scale, particularly for U.S.-facing development where the TSCA status must be confirmed rather than assumed.
For Russian and EAEU buyers, the strategic implication is that procurement should be treated as a specification-and-documentation decision rather than a price comparison. A nominal 96% lot that fails to meet the program’s purity requirement, or a shipment that arrives without a Russian-language SDS and lot-specific analytical data, can cost more in lost synthesis time than the price difference between two suppliers. The lowest-risk source is the one that can provide lot-specific HPLC data, confirm the 5-bromo-4-isopropyl-2-amino substitution pattern, clarify inventory status for U.S.-linked programs, and support the program as it scales.
Shanghai XinChem Co., Ltd. (XinChem)
As a world-leading supplier of organic chemicals, Shanghai XinChem Co., Ltd. (XinChem) offers 5-bromo-4-isopropylthiazol-2-amine (CAS 1025700-49-5) in research-grade and custom-synthesis specifications, serving medicinal chemistry groups, kinase inhibitor discovery programs, antiviral and antimicrobial researchers, and pharmaceutical process development organizations. Our material is supplied with lot-specific analytical data, controlled substitution-pattern purity and the documentation support that trifunctional thiazole building-block qualification requires at both catalogue and scale-up stages.
Technical and Quality Advantages
Lot-Specific HPLC Data and Substitution-Pattern Confirmation: 5-Bromo-4-isopropylthiazol-2-amine is supplied with a Certificate of Analysis reporting identity and purity by HPLC for the specific lot, with the 5-bromo-4-isopropyl-2-amino substitution pattern confirmed. Because each of the three positions determines a different reactivity—bromo for cross-coupling, amino for acylation or alkylation, isopropyl for lipophilicity and steric modulation—lot-level confirmation is more informative than a catalogue percentage, and it allows the medicinal chemist to qualify the material against the program’s actual requirements.
Purity at the ≥96% and ≥97% Thresholds with Grade Distinction: Material is available at ≥96% (HPLC), consistent with the standard research-grade specification, with ≥97% and ≥98% grades available for applications where a tighter impurity profile is required. The explicit grade distinction allows the buyer to match the specification to the stage of development rather than discovering after purchase that a nominal-grade lot requires additional purification.
Inventory-Status Clarity: XinChem provides a direct statement of the current inventory position relevant to the destination market, rather than relying on an inconsistent catalogue field. For U.S.-facing programs, this clarity supports the buyer’s assessment of whether an R&D-exempt pathway or a PMN is required for the intended use.
Custom Synthesis and Scale-Up Continuity: The compound is available from 100 mg and 250 mg qualification quantities through to custom-synthesis gram and tens-of-gram volumes, with the analytical method and impurity profile held constant across scales. This continuity reduces the re-qualification burden when a program advances from medicinal chemistry to process development.
Regulatory and Language Support: Safety data sheets are available in English and Russian, with documentation covering the GHS07 irritant classification (H302, H315, H319, H335) and the recommended storage conditions (2–8 °C, inert atmosphere, protected from light). For EAEU buyers, the Russian-language SDS and Certificate of Analysis support incoming qualification.
Packaging and Logistics Flexibility
5-Bromo-4-isopropylthiazol-2-amine is available in sealed 100 mg, 250 mg, 1 g, 5 g, 10 g and 25 g containers for research and medicinal chemistry use, with larger package sizes for custom-synthesis and process-development quantities. The product should be stored at 2–8 °C under inert atmosphere in a dark, dry, tightly sealed container. For Russia and EAEU destinations, XinChem arranges logistics with appropriate customs and transport documentation, including Russian-language SDS and Certificate-of-Analysis support, to reduce clearance friction for a building block that is sourced internationally at research and process scale.
Application Support and Supply Reliability
XinChem’s technical team assists with grade selection for JAK, BTK, CDK and PI3K inhibitor programs, antiviral and antimicrobial discovery, and cross-coupling strategy for the 5-bromo position or acylation/alkylation at the 2-amino group, and with the analytical and documentation requirements that trifunctional thiazole building-block qualification demands. Supply schedules accommodate both catalogue-scale qualification orders and custom-synthesis volumes, with stock held for the package sizes most commonly requested in medicinal chemistry programs.
Why Choose XinChem
Expertise: Deep experience in aminothiazole and halogenated heterocyclic building blocks, with application knowledge spanning kinase inhibitor discovery, antiviral and antimicrobial research and custom synthesis.
Consistency: Lot-specific control of identity, HPLC purity and substitution pattern—the parameters that determine whether the building block incorporates cleanly into a target inhibitor or introduces a purification burden.
Compliance Readiness: Documentation structured around the GHS07 irritant classification, destination-specific inventory status and EAEU documentation expectations, with Russian-language SDS support.
Responsiveness: Direct technical and commercial access, with order structures from 100 mg qualification quantities to custom-synthesis volumes.
Contact us now to discuss your 5-bromo-4-isopropylthiazol-2-amine requirements and request a specification sheet or qualification sample.
Website: www.xinchem.com
Email: sales1@xinchem.com
WhatsApp: +86 18049800532
Post time: Nov-01-2026